Wenqing Yin

Wenqing Yin

Auto-generated profile, based on publicly available information

Wenqing Yin

Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CLChimera Lyle
Chimera Lyle
SRSean Richards
Sean Richards
KYKei Yasuda
Kei Yasuda
MNMarc Arthur Napoleon
Marc Arthur Napoleon
JWJoshua Walker
Joshua Walker
VCVipul Chitalia
Vipul Chitalia
Casitas B lymphoma (c-Cbl) is an E3 ubiquitin ligase and a negative regulator of colorectal cancer (CRC). Despite its high expression in immune cells, the effect of c-Cbl on the tumor microenvironment remains poorly understood. Here we demonstrate that c-Cbl alters the tumor microenvironment and suppresses Programmed cell death-1 (PD-1) protein, an immune checkpoint receptor. Using syngeneic CRC xenografts, we observed significantly higher growth of xenografts and infiltrating immune cells in c-Cbl+/− compared to c-Cbl+/+ mice. Tumor-associated CD8+ T-lymphocytes and macrophages of c-Cbl+/− mice showed 2–3-fold higher levels of PD-1. Functionally, macrophages from c-Cbl+/− mice showed a 4–5-fold reduction in tumor phagocytosis, which was restored with an anti-PD-1 neutralizing antibody suggesting regulation of PD-1 by c-Cbl. Further mechanistic probing revealed that C-terminus of c-Cbl interacted with the cytoplasmic tail of PD-1. c-Cbl destabilized PD-1 through ubiquitination- proteasomal degradation depending on c-Cbl’s RING finger function. This data demonstrates c-Cbl as an E3 ligase of PD-1 and a regulator of tumor microenvironment, both of which were unrecognized components of its tumor suppressive activity. Advancing immune checkpoint and c-Cbl biology, our study prompts for probing of PD-1 regulation by c-Cbl in conditions driven by immune checkpoint abnormalities such as cancers and autoimmune diseases.

4 January 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NANkiruka V. Arinze
Nkiruka V. Arinze
WYWenqing Yin
Wenqing Yin
SLSaran Lotfollahzadeh
Saran Lotfollahzadeh
MNMarc Arthur Napoleon
Marc Arthur Napoleon
SRSean Richards
Sean Richards
VCVipul Chitalia
Vipul Chitalia
Chronic kidney disease (CKD) imposes a strong and independent risk for peripheral artery disease (PAD). While solutes retained in CKD patients (uremic solutes) inflict vascular damage, their role in PAD remains elusive. Here, we show that the dietary tryptophan-derived uremic solutes including indoxyl sulfate (IS) and kynurenine (Kyn) at concentrations corresponding to those in CKD patients suppress β-catenin in several cell types, including microvascular endothelial cells (ECs), inhibiting Wnt activity and proangiogenic Wnt targets in ECs. Mechanistic probing revealed that these uremic solutes downregulated β-catenin in a manner dependent on serine 33 in its degron motif and through the aryl hydrocarbon receptor (AHR). Hindlimb ischemia in adenine-induced CKD and IS solute–specific mouse models showed diminished β-catenin and VEGF-A in the capillaries and reduced capillary density, which correlated inversely with blood levels of IS and Kyn and AHR activity in ECs. An AHR inhibitor treatment normalized postischemic angiogenic response in CKD mice to a non-CKD level. In a prospective cohort of PAD patients, plasma levels of tryptophan metabolites and plasma’s AHR-inducing activity in ECs significantly increased the risk of future adverse limb events. This work uncovers the tryptophan metabolite/AHR/β-catenin axis as a mediator of microvascular rarefaction in CKD patients and demonstrates its targetability for PAD in CKD models.

13 December 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
PPPaul Pang
Paul Pang
MAMolly Abbott
Molly Abbott
MAMalyun Abdi
Malyun Abdi
QFQuynh-Anh Fucci
Quynh-Anh Fucci
NCNikita Chauhan
Nikita Chauhan
ASAndrew M Siedlecki
Andrew M Siedlecki
Chronic kidney disease (CKD) patients have deficient levels of glutathione peroxidase-3 (GPx3). We hypothesized that GPx3 deficiency may lead to cardiovascular disease in the presence of chronic kidney disease due to an accumulation of reactive oxygen species and decreased microvascular perfusion of the myocardium. To isolate the exclusive effect of GPx3 deficiency in kidney disease–induced cardiac disease, we studied the GPx3 knockout mouse strain (GPx3−/−) in the setting of surgery-induced CKD. Ribonucleic acid (RNA) microarray screening of non-stimulated GPx3−/− heart tissue show increased expression of genes associated with cardiomyopathy including myh7, plac9, serpine1 and cd74 compared with wild-type (WT) controls. GPx3−/− mice underwent surgically induced renal mass reduction to generate a model of CKD. GPx3−/− + CKD mice underwent echocardiography 4 weeks after injury. Fractional shortening (FS) was decreased to 32.9 ± 5.8% in GPx3−/− + CKD compared to 62.0% ± 10.3 in WT + CKD (P < 0.001). Platelet aggregates were increased in the myocardium of GPx3−/− + CKD. Asymmetric dimethylarginine (ADMA) levels were increased in both GPx3−/− + CKD and WT+ CKD. ADMA stimulated spontaneous platelet aggregation more quickly in washed platelets from GPx3−/−. In vitro platelet aggregation was enhanced in samples from GPx3−/− + CKD. Platelet aggregation in GPx3−/− + CKD samples was mitigated after in vivo administration of ebselen, a glutathione peroxidase mimetic. FS improved in GPx3−/− + CKD mice after ebselen treatment. These results suggest GPx3 deficiency is a substantive contributing factor to the development of kidney disease–induced cardiac disease.

26 December 2019 in Blood
Verified
Journal Article
Open access
PDF file
MBMostafa Belghasem
Mostafa Belghasem
DRDaniel Roth
Daniel Roth
SRSean Richards
Sean Richards
MNMarc Arthur Napolene
Marc Arthur Napolene
JWJoshua Walker
Joshua Walker
VCVipul Chitalia
Vipul Chitalia
Currently, we have insufficient understanding of venous thromboembolism in cancer patients. In this article, the authors reveal a novel mechanism for colon cancer-associated venous thrombosis using a murine model.

4 November 2015 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
WYWenqing Yin
Wenqing Yin
SNSaid Movahedi Naini
Said Movahedi Naini
GCGuochun Chen
Guochun Chen
DHDirk M. Hentschel
Dirk M. Hentschel
BHBenjamin D. Humphreys
Benjamin D. Humphreys
JBJoseph V Bonventre
Joseph V Bonventre
Kidney injury molecule 1 (KIM-1), an epithelial phagocytic receptor, is markedly upregulated in the proximal tubule in various forms of acute and chronic kidney injury in humans and many other species. Whereas acute expression of KIM-1 has adaptive anti-inflammatory effects, chronic expression may be maladaptive in mice. Here, we characterized the zebrafish Kim family, consisting of Kim-1, Kim-3, and Kim-4. Kim-1 was markedly upregulated in kidney after gentamicin-induced injury and had conserved phagocytic activity in zebrafish. Both constitutive and tamoxifen-induced expression of Kim-1 in zebrafish kidney tubules resulted in loss of the tubule brush border, reduced GFR, pericardial edema, and increased mortality. Kim-1-induced kidney injury was associated with reduction of growth of adult fish. Kim-1 expression led to activation of the mammalian target of rapamycin (mTOR) pathway, and inhibition of this pathway with rapamycin increased survival. mTOR pathway inhibition in KIM-1-overexpressing transgenic mice also significantly ameliorated serum creatinine level, proteinuria, tubular injury, and kidney inflammation. In conclusion, persistent Kim-1 expression results in chronic kidney damage in zebrafish through a mechanism involving mTOR. This observation predicted the role of the mTOR pathway and the therapeutic efficacy of mTOR-targeted agents in KIM-1-mediated kidney injury and fibrosis in mice, demonstrating the utility of the Kim-1 renal tubule zebrafish models.

31 October 2020 in Cells
Verified
Journal Article
Open access
PDF file
MKMohamed Hassan Kamel
Mohamed Hassan Kamel
WYWenqing Yin
Wenqing Yin
CZChris Zavaro
Chris Zavaro
JFJean M. Francis
Jean M. Francis
VCVipul Chitalia
Vipul Chitalia
COVID-19 infection has protean systemic manifestations. Experience from previous coronavirus outbreaks, including the current SARS-CoV-2, has shown an augmented risk of thrombosis of both macrovasculature and microvasculature. The former involves both arterial and venous beds manifesting as stroke, acute coronary syndrome and venous thromboembolic events. The microvascular thrombosis is an underappreciated complication of SARS-CoV-2 infection with profound implications on the development of multisystem organ failure. The telltale signs of perpetual on-going coagulation and fibrinolytic cascades underscore the presence of diffuse endothelial damage in the patients with COVID-19. These parameters serve as strong predictors of mortality. While summarizing the alterations of various components of thrombosis in patients with COVID-19, this review points to the emerging evidence that implicates the prominent role of the extrinsic coagulation cascade in COVID-19-related coagulopathy. These mechanisms are triggered by widespread endothelial cell damage (endotheliopathy), the dominant driver of macro- and micro-vascular thrombosis in these patients. We also summarize other mediators of thrombosis, clinically relevant nuances such as the occurrence of thromboembolic events despite thromboprophylaxis (breakthrough thrombosis), current understanding of systemic anticoagulation therapy and its risk–benefit ratio. We conclude by emphasizing a need to probe COVID-19-specific mechanisms of thrombosis to develop better risk markers and safer therapeutic targets.